Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation
© The Author(s). 2017
Received: 21 December 2016
Accepted: 23 February 2017
Published: 10 March 2017
Growing evidence suggests that hepatitis C virus (HCV) contributes to hepatocellular carcinoma (HCC) by directly modulating oncogenic signaling pathways. Protein phosphatase magnesium-dependent 1A (PPM1A) has recently emerged as an important tumor suppressor as it can block a range of tumor-centric signaling pathways through protein dephosphorylation. However, the role and regulatory mechanisms of PPM1A in HCV-infected cells have not been reported.
Total, cytoplasmic, and nuclear PPM1A protein after HCV infection or overexpression of HCV nonstructural protein 3 (NS3) were detected by western blotting. The expression of PPM1A in normal liver and HCV-related HCC tissues was quantified by immunohistochemistry. The effects of HCV infection and NS3 expression on the PPM1A protein level were systematically analyzed, and the ubiquitination level of PPM1A was determined by precipitation with anti-PPM1A and immunoblotting with either anti-ubiquitin or anti-PPM1A antibody. Finally, the roles of NS3 and PPM1A in hepatoma cell migration and invasion were assessed by wound healing and transwell assays, respectively.
HCV infection and replication decreased PPM1A abundance, mediated by NS3, in hepatoma cells. Compared to normal liver tissues, the expression of PPM1A was significantly decreased in the HCC tumor tissues and adjacent non-tumor tissues. NS3 directly interacted with PPM1A to promote PPM1A ubiquitination and degradation, which was dependent on its protease domain. Blockade of PPM1A through small interfering RNA significantly promoted HCC cell migration, invasion, and epithelial mesenchymal transition (EMT), which were further intensified by TGF-β1 stimulation, in vitro. Furthermore, restoration of PPM1A abrogated the NS3-mediated promotion of HCC migration and invasion to a great extent, which was dependent on its protein phosphatase function.
Our findings demonstrate that the HCV protein NS3 can downregulate PPM1A by promoting its ubiquitination and proteasomal degradation, which might contribute to the migration and invasion of hepatoma cells and may represent a new strategy of HCV in carcinogenesis.
KeywordsHepatocellular carcinoma Hepatitis C virus PPM1A Cancer cell invasion Ubiquitination and degradation
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China . It ranks as the fifth most common malignancy and the second leading cause of cancer deaths worldwide, with more than 695,900 deaths each year. Chronic hepatitis C virus (HCV) infection is one of the most important risk factors for developing HCC . Approximately 200 million people are infected with HCV worldwide, and up to 80% of infected individuals progress to chronic hepatitis, which results in liver cirrhosis and HCC in many cases [3, 4]. Although some progress has been made, the mechanism underlying HCV-associated hepatocarcinogenesis remains not fully understood.
HCV is a positive single-stranded RNA virus with an exclusively cytoplasmic life cycle. Unlike hepatitis B virus (HBV), which is a DNA virus that can induce insertional mutagenesis, HCV does not insert into the host cell genome . Although the inflammation caused by chronic hepatitis C is likely to contribute to the development of HCC, there is strong evidence that one or more of the viral proteins and its involvement in interrupting cellular signaling pathways contribute mostly to tumorigenesis . Multiple cellular signaling pathways including the Wnt/β-catenin, p53, pRb, MAPK pathways, and particularly, the TGF-β/smad pathway, have been implicated in hepatocarcinogenesis [6–8]. TGF-β appears to play an important role in the pathogenesis of HCC and is considered a hallmark of HCC because it is elevated in the serum, tissue, and urine of patients and the increased levels correlate with tumor progression and survival [9–11]. Furthermore, TGF-β can induce a protumoral transcriptional program in cells that express HCV subgenomic replicon . Moreover, previous studies have shown that blockade of the TGF-β signaling pathway using inhibitors dramatically suppresses HCC cell invasiveness and metastasis . As these signaling pathways are all associated with the development of HCC, targeting and/or blocking of these pathways can be expected to contribute to new strategies for suppressing tumorigenesis and disease progression.
PPM1A, also known as PP2Cα, is a protein phosphatase that belongs to the Protein Phosphatase 2C family. PPM1A has recently emerged as an important tumor suppressor owing to its involvement in the regulation of several tumor-centric signaling pathways, including TGF-β/smad , Wnt/β-catenin , MAPK , PI3K/Akt , and NF-κB [18, 19]. The regulation of these pathways has been attributed to PPM1A phosphatase activity towards important pathway components (e.g., p-Smad2/3 in TGF-β, Axin in Wnt, p38 in MAPK, p85 subunit of PI3K in PI3K, and RelA and IKKβ in NF-κB). Moreover, overexpression of PPM1A led to cell cycle arrest in G2/M and apoptosis by inducing both the expression and transcriptional activity of p53, although it remains unclear how PPM1A modulates p53 activity . Importantly, several tumor tissues, including metastatic human prostate and bladder carcinomas, have shown decreased or loss of PPM1A expression [18, 21]. This indicates that modulation of the protein level of PPM1A might be an effective strategy for the abnormal activation of the signal pathway in tumor progression. However, the expressional regulation and distinct functions of PPM1A in regulating tumor cells remain largely unknown.
In this study, we examined the expression of PPM1A in HCV-infected hepatoma cells and HCV-related HCC tissues, and we determined whether this protein is involved in HCV-related HCC development. We found a direct link between HCV infection and cellular abundance of PPM1A in both hepatoma cells and the HCC tissues. The mechanism by which NS3 downregulates PPM1A abundance was revealed, and the roles of PPM1A in regulating hepatoma cell invasion and migration were assessed in vitro. Together, our findings provide novel evidence on the mechanisms involved in HCV-mediated progression of HCC, which may provide potential candidates for the clinical prevention and treatment of HCV-associated HCC.
Cell culture and virus preparation
Human HCC cells (Huh-7 and Huh-7.5.1) and embryo kidney cells (HEK293T) were purchased from the China Center for Typical Culture Collection (Wuhan, China). Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin in an incubator at 37 °C with 5% CO2. The genotype 2a HCV strain JFH1 was kindly gifted by Dr. Ying Zhu. Three days after infection of Huh-7.5.1 cells with JFH1, cell culture supernatant containing HCV particles (HCVcc) was collected, filtered using a 0.45-μm filter, and stored at −80 °C for later infection of Huh-7 cells. HCV titers were measured using a HCV RNA qPCR Diagnostic Kit (KHB Co., Shanghai, China).
Reagents and antibodies
Protein synthesis inhibitor cycloheximide (CHX, 300 μM), proteasome inhibitor MG132 (20 μM), and autophagy inhibitor chloroquine (diphosphate salt, 50 μM) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All inhibitors were dissolved in DMSO and used at the final concentrations indicated above. Recombinant Human TGF-β1 was purchased from PeproTech (Rocky Hill, NJ, USA), dissolved in citric acid buffer (10 mM, pH 3.0) at a concentration of 1 mg/ml, and used at a final concentration of 200 pM.
Mouse monoclonal antibodies against HCV NS3 and core protein were obtained from Abcam (Cambridge, MA, USA) and Thermo Fisher Scientific (Waltham, MA, USA), respectively. Rabbit polyclonal antibody against HCV NS5A was purchased from ViroGen (Watertown, MA, USA). Antibodies against PPM1A, E-cadherin, N-cadherin, and vimentin were purchased from Cell Signaling Technology (Danvers, MA, USA), and antibodies against Flag and GFP were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Clinical specimens and immunohistochemistry
Twelve pairs of HCV-related HCC tumor tissues and matched adjacent non-tumor tissues, and 10 normal liver tissue samples were collected at the Department of Pathology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, between 2015 and 2016. The study was approved by the ethics committee of Tongji Medical College, and informed consent was obtained from all participants. Immunohistochemical staining analyses were performed using 4-μm formalin-fixed paraffin-embedded tissue sections. The sections were deparaffinized, rehydrated, and incubated in EDTA at 120 °C for 5 min for antigen retrieval. After incubation with 3% H2O2 at room temperature for 15 min, the sections were blocked with fetal bovine serum and incubated with primary antibodies overnight. Immunodetection was performed with HRP-conjugated goat anti-rabbit antibody. Finally, the immune complexes were visualized with a chromogenic substrate (DAB; DAKO, Glostrup, Denmark), and the sections were counterstained with hematoxylin.
The score of PPM1A staining was determined and evaluated as described by Soslow RA et al. . Briefly, the staining intensity was evaluated independently by two experienced pathologists and was given a score from 0 to 3 (0 = no, 1 = weak, 2 = moderate, 3 = strong staining). The intensity score was multiplied by the proportion of cells stained (%) to give a final score.
Plasmids and transfection
Flag-PPM1A (pRK5F) and Flag-PPM1A D239N (pRK5F), the phosphatase-dead mutant of PPM1A, were provided as a gift by Dr. Xinhua Feng . Flag-tagged expression plasmids for HCV core, P7, E1, E2, NS2, NS3, NS4A, NS4B, NS5A, and NS5B proteins (pCMV-tag2B) were generously gifted by Dr. Ying Zhu. To construct the GFP-tagged NS3 and NS3 deletion constructs (protease and helicase domains of NS3), corresponding sequences were amplified by PCR using Flag-NS3 as the template and were subcloned into the pGFP vector (Clontech Laboratories Inc., Mountain View, CA, USA) to derive pGFP-NS3, pGFP-protease, and pGFP-helicase. Site-directed mutagenesis was carried out according to the manufacturer’s instructions (TransGen Biotech, Beijing, China) to convert the serine codon at position 139 of wild-type NS3 to an alanine codon to create a protease-inactive mutant of NS3, called S139A. All constructs containing PCR fragments were confirmed by DNA sequencing.
Cells were grown to 50% confluence in 6-well plates, and transfections were conducted with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. In all co-transfection experiments, corresponding vectors were used as negative controls to ensure similar DNA concentrations. Cells were either used at 24 h post-transfection for wound healing and invasion assay, or at 36 h for western blotting.
RNA interference analysis
Short interfering RNA (siRNA) against PPM1A (si-PPM1A) and negative control (si-NC) with nonspecific targeting sequences were synthesized by GenePharma Co. (Shanghai, China). The sequences were as follows:
PPM1A siRNA 1 (5′-GTACCTGGAATGCAGAGTA-3′); PPM1A siRNA 2 (5′-GTCGACACCTGTTTGTATA-3′); NC (non-targeting) siRNA (5′-TTCTCCGAACGTGTCACGT-3′). Huh-7 cells were grown to 40% confluence in 6-well plates and transiently transfected with 100 nM siRNAs using Lipofectamine 2000. The cells were used either for in vitro wound healing and invasion assays after 24 h of transfection or for western blotting after 36 h.
RNA isolation and quantitative reverse transcription (qRT-)PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen) and mRNA was reverse transcribed using a Revert Aid First-Strand cDNA Synthesis Kit (Thermo Fisher) according to the manufacturer’s instructions. qPCR was carried out with 2× SYBR Green Mix (Thermo Fisher) on a LightCycler 480II (Roche). The primers used in real-time PCR were as follows:
GAPDH: (F: 5′-GGTGAAGGTCGGAGTCAACGG-3′; R: 5′-GAGGTCAATGAAGGGGTCATTG-3′), PPM1A: (F: 5′-CGCTGGAGAAAGAACGAAT-3′; R: 5′-TCTCTATCTGCCCACAGCCTAC-3′). HCV: (F: 5′-TCTGCGGAACCGGTGAGTA-3′; R: 5′-TCAGGCAGTACCACAAGGC-3′). The data were normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Relative expression was calculated using the 2-ΔΔCt method.
Total protein was extracted using RIPA protein lysis buffer (Beyotime, Shanghai, China) with freshly added 1% protease inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cell fractions were prepared using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime) according to the manufacturer’s protocol. In total, 50 μg of protein was used for western blotting. Samples were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking in 5% skim milk, the PVDF blots were incubated with primary antibodies in blocking buffer overnight at 4 °C and then with HRP-conjugated secondary antibody for 2 h. Reactive bands were visualized with ECL reagent (Pierce, Rockford, IL) and analyzed. Protein expression was quantified using ImageJ software.
Cells were washed twice with ice-cold PBS and lysed in Triton-lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 2 mM dithiothreitol (DTT), 0.5% Triton X-100, 1% protease inhibitor cocktail, and 1 mM PMSF]. The lysates were centrifuged at 12,000 × g for 10 min at 4 °C and supernatant was precleared with 20 μL Protein A/G PLUS-Agarose (Santa Cruz, CA, USA) for 1 h at 4 °C. The lysates were incubated with the appropriate antibody overnight at 4 °C, followed by precipitation with protein A/G PLUS-Agarose. The immunoprecipitates were collected by washing and centrifugation for three times, boiled in 2× SDS sample buffer, and subjected to western blotting.
Cells grown on coverslips were washed twice with ice-cold PBS, fixed in 4% paraformaldehyde, permeabilized with 0.3% Triton X-100 for 10 min, and blocked with 3% bovine serum albumin. Then, the cells were incubated with primary antibodies, followed by Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibody (Molecular Probes, OR, USA). Nuclei were stained with DAPI.
In vitro invasion assay
Twenty-four-well transwell plates with 8-μm pore-size polycarbonate membrane inserts (Corning, NY, USA) were precoated with 80 μL of 1:8 DMEM-diluted Matrigel (BD Biosciences, CA, USA). Cells (5 × 104) were seeded in serum-free medium in the top chamber and allowed to invade into the lower chamber, which contained 20% FBS as a chemoattractant. TGF-β1 or vehicle was added to the upper and lower chambers. After 24 h, cells that had invaded into the lower surface of the membrane were fixed in 100% methanol, stained with 0.1% crystal violet, and quantified by counting in five random fields.
In vitro wound healing assay
Cells grown to confluence in 24-well transwell plates were manually scratched with a micropipette tip to create uniformly sized wounds. Then, the cell culture medium was replaced with fresh FBS-free medium, and TGF-β1 or vehicle was added as required. Four points were randomly selected and marked for each scratch, and healing wounds were imaged at 36 h. The percentage of wound closure was calculated based on the initial measurement for that point at time point zero.
All values are presented as the mean ± standard error (SEM) from at least three independent experiments. Differences between group means were determined using a two-tailed Student’s t-test or one-way ANOVA. A P-value <0.05 was considered statistically significant.
HCV infection downregulates PPM1A abundance
To further examine how HCV affects the expression of PPM1A in HCC, we used immunohistochemistry to assess the expression levels of PPM1A in HCV-related HCC and normal liver tissues. As shown in Fig. 1g, compared with the normal liver tissues, significantly lower levels of PPM1A were found in the HCC tumor and adjacent tissues. In addition, there were no significant differences in PPM1A expression between tumor tissues and the paired adjacent non-tumor tissues. Together, these results provided strong evidence that PPM1A is downregulated in HCV-infected hepatoma cells.
NS3 protein mediates the regulation of PPM1A
NS3 is a serine protease that cleaves its substrates . It is possible that the reduction of PPM1A is caused by its protease activity. Thus, a protease-inactive mutant of NS3, S139A, was constructed . S139A had the same effect as the wild type on the expression of PPM1A (Fig. 2c), indicating that the protease activity is not necessary for the effect of NS3 on PPM1A expression.
Full-length NS3 and the NS3 protease domain are diffusely distributed in the cytoplasm and nucleus in the absence of the cofactor NS4A, while in the presence of NS4A, NS3 is localized exclusively in the cytoplasm . The current study confirmed the cytoplasmic and nuclear distribution of NS3. Furthermore, it was shown that in GFP- and non-transfected cells, PPM1A was localized mainly in the nucleus. In contrast, in NS3-transfected cells, PPM1A demonstrated a more diffuse pattern throughout the cytoplasm and the nucleus, and total fluorescence intensity was strikingly reduced (Fig. 2d). Collectively, these results suggested that the HCV protein NS3 is sufficient to modulate the abundance and cellular localization of PPM1A.
NS3 interacts with PPM1A
To determine which domain(s) of NS3 mediates its interaction with PPM1A, two deletion constructs were made to separately express either the protease (aa 1–180) or the helicase (aa 181–631) domain of NS3. Co-immunoprecipitation revealed that while the protease domain of NS3 interacted with PPM1A, the helicase domain did not (Fig. 3c). This suggested that the protease domain is responsible for the interaction of the full-length NS3 with PPM1A. Similarly, the protease domain of NS3 could translocate PPM1A from the nucleus to the cytoplasm (Fig. 2d). These results suggested that NS3 interacts with PPM1A through its protease domain.
HCV infection and NS3 expression promote ubiquitin-mediated proteasomal degradation of PPM1A
Eukaryotic cells use the ubiquitin proteasome system (UPS) and autophagy lysosome pathway (ALP) as major protein degradation pathways . Treatment of NS3-transfected cells with UPS inhibitor MG132 or ALP inhibitor chloroquine revealed that MG132 almost completely abolished the effect of NS3 on the PPM1A protein level (Fig. 4c). This indicated that NS3 might affect the proteasomal degradation of PPM1A.
Since ubiquitination is generally enhanced prior to proteasomal degradation , we examined whether HCV infection and NS3 expression enhanced the ubiquitination of PPM1A. Huh-7 cells were infected with JFH1 virus for 72 h, then treated without or with MG132 for 12 h, and immunoprecipitation experiments with an antibody specific for PPM1A were performed. Ubiquitinated PPM1A was detected using an anti-ubiquitin antibody. Apparently, the levels of ubiquitinated PPM1A were significantly higher in HCV-infected than in control cells (Fig. 4d). Moreover, NS3 overexpression also elevated the ubiquitinated PPM1A levels (Fig. 4e). Taken together, these results indicated that HCV NS3 protein downregulates PPM1A protein level by promoting its ubiquitin-dependent proteasomal degradation.
PPM1A overexpression reverses NS3-mediated enhancement on cell invasion
Epithelial-mesenchymal transition (EMT) has been associated with the acquisition of motility, invasiveness, and self-renewal traits in HCC cells . In this study, sole expression of the viral protein NS3 significantly increased vimentin and N-cadherin expression and decreased E-cadherin expression, while restoration of PPM1A expression nearly abrogated the EMT-promoting effect of NS3 (Fig. 5c). Moreover, we found that the phosphatase-dead mutant PPM1A D239N could not abolish the enhancing effect of NS3, which suggests that the function of PPM1A depends on its phosphatase activity (Fig. 5a and b). Together, these results suggested that the cellular invasion capacity caused by NS3 is mediated at least partially through the modulation of PPM1A abundance.
Downregulation of PPM1A promotes the invasive capacity of Huh-7 cells in vitro, and this promotional effect is intensified by TGF-β1 stimulation
In accordance herewith, PPM1A-knockdown cells showed increased vimentin and N-cadherin expression, but decreased E-cadherin expression, when compared to control cells (Fig. 6e). These results demonstrated that the reduced expression of PPM1A resulted in a more pronounced EMT phenotype, which might contribute to the acquisition of tumor-initiating and malignancy-associated traits.
Increasing experimental evidence suggests that HCV contributes to HCC by directly modulating signaling pathways that promote the malignant transformation of hepatocytes. Among the HCV-encoded proteins, the core protein, NS3, NS4B, and NS5A have received much attention, since all of them possess cell-transforming potential by interacting with a number of host factors and signaling pathways when expressed in cell culture or transgenic animal models [6, 29]. NS3, a non-structural protein of HCV, contains a protease and a helicase domain and plays crucial roles in the processing of the viral polyprotein, viral RNA replication, and translation . Previous studies have shown that NS3 protein modulates various signaling pathways that have transforming potential . In this study, we found a new strategy adopted by NS3 to promote the invasion and metastasis of HCC cells through promoting the ubiquitination and degradation of PPM1A.
Although PPM1A was first identified approximately 20 years ago and a number of achievements with regard to revealing its functions have been made, studies on the mechanisms of PPM1A regulation have been rarely reported. In this study, we found that PPM1A was strongly downregulated and its normal nuclear localization shifted to a mainly cytoplasmic distribution following infection of cultured hepatoma cells with HCV. A screening of HCV proteins revealed that NS3 was responsible for this alteration. Our results are consistent with a mechanism in which NS3 forms a complex with PPM1A, thereby accelerating its degradation, since we showed that the stability of PPM1A is reduced in cells expressing NS3 protein. In addition, we observed a restoration of PPM1A abundance after treatment of NS3-expressing cells with proteasome inhibitors, and the amount of ubiquitin-complex PPM1A increased in HCV-infected as well as NS3-expressing cells, which suggests that NS3 modulates the abundance of PPM1A via the cellular normal protein degradation pathway. Significantly lower levels of PPM1A were also found in HCV-related HCC and adjacent tissues than in normal tissues. However, our data did not reveal a direct correlation between PPM1A and NS3 expression in HCC tissues because of the low level of HCV antigen expression in HCC tissues and the lack of an antibody capable of labeling the HCV protein in infected liver tissues .
The participation of HCV proteins in the ubiquitination and degradation of host proteins has been reported. Munakata et al. found that HCV NS5B protein traps retinoblastoma tumor-suppressor protein (pRb) in the cytoplasm and subsequently recruits E6AP to this complex, which leads to the ubiquitination and degradation of pRb . NS3 can also interact with several components of the UPS, including the E3 ubiquitin ligase components DDB1 , LUBAC , and SMURF2 , which suggests that the utilization of the UPS by HCV proteins has become one of the strategies of HCV for promoting HCC progression and viral replication. However, the precise molecular mechanism underlying the enhancement of PPM1A ubiquitination by NS3 remains elusive and warrants further studies.
Recently, PPM1A has attracted increasing interest owing to its tumor suppressor-like activity. Lu et al.  found that decreased PPM1A expression enhances prostate cancer metastasis and this, at least partially, depends on its ability to inhibit NF-κB signaling. In metastatic bladder cancer, loss of PPM1A expression significantly promoted urinary bladder cancer cell motility, EMT in vitro, and metastasis in vivo, which were dependent on the TGF-β/smad signaling pathway . Similarly, we found that knockdown of PPM1A significantly promoted HCC cell migration and invasion in vitro, and the promotional activity was further intensified by TGF-β1 stimulation. These results show that loss of PPM1A may play an important role in the tumorigenesis of HCC, and that it partially depends on the TGF-β/smad signaling pathway. Since multiple tumor-related pathways can be modulated by PPM1A, further studies on the exact signaling pathway and its corresponding function in HCC tumorigenesis are needed.
Lin et al.  found that endogenous PPM1A is primarily localized in the nucleus, where it dephosphorylates and promotes the nuclear export of TGF-β-activated Smad2/3. This study corroborated that PPM1A is normally localized in the nucleus. When NS3 was expressed, PPM1A was shuttled to the cytoplasm and it demonstrated a more diffuse pattern throughout the cells. The alteration of PPM1A subcellular localization may be partially caused by an interaction with NS3, which localizes in the cytoplasm in the presence of NS4A . It is likely that NS3 interacts with and traps PPM1A in the cytoplasm where HCV completes its lifecycle, thereby accelerating its degradation. Since the effect of PPM1A on TGF-β signaling is dependent on its nuclear localization, we speculate that, in addition to a decrease in the abundance of PPM1A, its cytoplasmic redistribution might be another means to enhance TGF-β signaling. It will be of great interest to explore how the subcellular localization of PPM1A is regulated in order to control TGF-β and other signaling pathways under physiological and pathophysiological conditions.
Furthermore, we found that the rescue of PPM1A expression partially counteracted the promotional effect of NS3 on HCC cell migration and invasion, and that the rescuing efficiency depended on its protein phosphatase function as phosphatase-dead mutants of PPM1A had no effect. It is worth noting that restoration of PPM1A could only partially abrogate this promotional effect, suggesting that NS3 possesses additional carcinogenesis activity. In fact, the oncogenic properties of NS3 may involve a variety of signal-transduction pathways. In addition to modulating the TGF-β pathway by targeting SMURF2 , NS3 can also enhance cancer cell invasion by activating matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2 (COX-2) through the ERK/p38/NF-κB signal cascade , and interact with p53 to inhibit p53-dependent transcription . These findings strongly suggest that the inhibition of PPM1A by NS3 may be a novel mechanism of HCV-mediated carcinogenesis.
Interestingly, during the course of the present study, Liu et al.  reported that the HBV X protein (HBX) increased the ubiquitination and degradation of PPM1A, which is responsible for the HBX-induced promotion of HCC carcinogenesis. This suggests that PPM1A, a key modulator of the signaling pathway, can be targeted and degraded by more than one hepatitis viral protein, and that this has become one of the strategies of the virus to promote tumor progression.
We proposed a new mechanism by which HCV protein NS3 enhances cancer cell invasion and migration through promoting the ubiquitination and degradation of PPM1A. These findings not only substantiate the critical role of NS3 in developing cancer, but also suggest that strategies to increase PPM1A expression or activity in cancer cells could be explored as a therapeutic strategy for HCC prevention and treatment. However, further studies in vivo should be performed to validate the function and mechanisms of PPM1A.
Autophagy lysosome pathway
Epithelial mesenchymal transition
Hepatitis B virus
Hepatitis C virus
Human hepatoma cell
The genotype 2a HCV strain JFH1
Mitogen-activated protein kinase
HCV nonstructural protein 3
Tumor protein p53
Protein phosphatase magnesium-dependent 1A
Retinoblastoma tumor-suppressor protein
Transforming growth factor β
Ubiquitin proteasome system
We are grateful to Dr. Xinhua Feng (Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University) for kindly providing the PPM1A and PPM1A D239N plasmids.
This work was supported by the National Natural Science Foundation of China (31070142) and Open Research Fund Program of the State Key Laboratory of Virology of China (2014KF007).
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
Hongmei Yang, Xiaoping Zhang and Yali Zhou designed the studies and drafted the manuscript. Yali Zhou, Yan Zhao, Yaoying Gao, Wenjun Hu and Yan Qu carried out all the experiments, prepared figures. Ning Lou and Ying Zhu contributed reagents and materials. All authors read and approved the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The study was approved by the ethics committee of Tongji Medical College, Huazhong University of Science and Technology, and informed consent was obtained from all participants.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5–s16.View ArticlePubMedGoogle Scholar
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.View ArticlePubMedGoogle Scholar
- Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.View ArticlePubMedGoogle Scholar
- Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007;5(6):453–63.View ArticlePubMedGoogle Scholar
- Jeong SW, Jang JY, Chung RT. Hepatitis C virus and hepatocarcinogenesis. Clin Mol Hepatol. 2012;18(4):347–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 2006;25(27):3834–47.View ArticlePubMedGoogle Scholar
- Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol. 2015;10:345–70.View ArticlePubMedGoogle Scholar
- Tang B, Tang F, Wang Z, Qi G, Liang X, Li B, Yuan S, Liu J, Yu S, He S. Overexpression of CTNND1 in hepatocellular carcinoma promotes carcinous characters through activation of Wnt/beta-catenin signaling. J Exp Clin Cancer Res. 2016;35(1):82.View ArticlePubMedPubMed CentralGoogle Scholar
- Bedossa P, Peltier E, Terris B, Franco D, Poynard T. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology (Baltimore, Md). 1995;21(3):760–6.Google Scholar
- Tsai JF, Chuang LY, Jeng JE, Yang ML, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine. 1997;76(3):213–26.View ArticlePubMedGoogle Scholar
- Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, Antonaci S. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol. 2002;161(1):183–93.View ArticlePubMedPubMed CentralGoogle Scholar
- Verga-Gerard A, Porcherot M, Meyniel-Schicklin L, Andre P, Lotteau V, Perrin-Cocon L. Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF-beta signaling. FASEB J. 2013;27(10):4027–40.View ArticlePubMedGoogle Scholar
- Giannelli G, Mazzocca A, Fransvea E, Lahn M, Antonaci S. Inhibiting TGF-beta signaling in hepatocellular carcinoma. Biochim Biophys Acta. 2011;1815(2):214–23.PubMedGoogle Scholar
- Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006;125(5):915–28.View ArticlePubMedGoogle Scholar
- Strovel ET, Wu D, Sussman DJ. Protein phosphatase 2Calpha dephosphorylates axin and activates LEF-1-dependent transcription. J Biol Chem. 2000;275(4):2399–403.View ArticlePubMedGoogle Scholar
- Takekawa M, Maeda T, Saito H. Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways. EMBO J. 1998;17(16):4744–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshizaki T, Maegawa H, Egawa K, Ugi S, Nishio Y, Imamura T, Kobayashi T, Tamura S, Olefsky JM, Kashiwagi A. Protein phosphatase-2C alpha as a positive regulator of insulin sensitivity through direct activation of phosphatidylinositol 3-kinase in 3 T3-L1 adipocytes. J Biol Chem. 2004;279(21):22715–26.View ArticlePubMedGoogle Scholar
- Lu X, An H, Jin R, Zou M, Guo Y, Su PF, Liu D, Shyr Y, Yarbrough WG. PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene. 2014;33(22):2918–27.View ArticlePubMedGoogle Scholar
- Sun W, Yu Y, Dotti G, Shen T, Tan X, Savoldo B, Pass AK, Chu M, Zhang D, Lu X, et al. PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. Cell Signal. 2009;21(1):95–102.View ArticlePubMedGoogle Scholar
- Ofek P, Ben-Meir D, Kariv-Inbal Z, Oren M, Lavi S. Cell cycle regulation and p53 activation by protein phosphatase 2C alpha. J Biol Chem. 2003;278(16):14299–305.View ArticlePubMedGoogle Scholar
- Geng J, Fan J, Ouyang Q, Zhang X, Zhang X, Yu J, Xu Z, Li Q, Yao X, Liu X, et al. Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-beta/Smad signaling pathway. Oncotarget. 2014;5(14):5700–11.View ArticlePubMedPubMed CentralGoogle Scholar
- Ramage HR, Kumar GR, Verschueren E, Johnson JR, Von Dollen J, Johnson T, Newton B, Shah P, Horner J, Krogan NJ, et al. A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol Cell. 2015;57(2):329–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Raney KD, Sharma SD, Moustafa IM, Cameron CE. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem. 2010;285(30):22725–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Lai VC, Zhong W, Skelton A, Ingravallo P, Vassilev V, Donis RO, Hong Z, Lau JY. Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus. J Virol. 2000;74(14):6339–47.View ArticlePubMedPubMed CentralGoogle Scholar
- Wolk B, Sansonno D, Krausslich HG, Dammacco F, Rice CM, Blum HE, Moradpour D. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol. 2000;74(5):2293–304.View ArticlePubMedPubMed CentralGoogle Scholar
- Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. 2010;584(7):1393–8.View ArticlePubMedGoogle Scholar
- Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001;70:503–33.View ArticlePubMedGoogle Scholar
- Yoshida GJ. Emerging role of epithelial-mesenchymal transition in hepatic cancer. J Exp Clin Cancer Res. 2016;35(1):141.View ArticlePubMedPubMed CentralGoogle Scholar
- Mileo AM, Mattarocci S, Matarrese P, Anticoli S, Abbruzzese C, Catone S, Sacco R, Paggi MG, Ruggieri A. Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation. J Exp Clin Cancer Res. 2015;34:140.View ArticlePubMedPubMed CentralGoogle Scholar
- Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takigawa Y, Ikeda M, Kato N, Sada K, Hotta H. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol. 2006;87(Pt 6):1703–13.View ArticlePubMedGoogle Scholar
- Harouaka D, Engle RE, Wollenberg K, Diaz G, Tice AB, Zamboni F, Govindarajan S, Alter H, Kleiner DE, Farci P. Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue. Proc Natl Acad Sci U S A. 2016;113(5):1375–80.View ArticlePubMedPubMed CentralGoogle Scholar
- Munakata T, Liang Y, Kim S, McGivern DR, Huibregtse J, Nomoto A, Lemon SM. Hepatitis C virus induces E6AP-dependent degradation of the retinoblastoma protein. PLoS Pathog. 2007;3(9):1335–47.View ArticlePubMedGoogle Scholar
- Kang X, Chen X, He Y, Guo D, Guo L, Zhong J, Shu HB. DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication. Virology. 2013;435(2):385–94.View ArticlePubMedGoogle Scholar
- Chen Y, He L, Peng Y, Shi X, Chen J, Zhong J, Chen X, Cheng G, Deng H. The hepatitis C virus protein NS3 suppresses TNF-alpha-stimulated activation of NF-kappaB by targeting LUBAC. Sci Signal. 2015;8(403):ra118.View ArticlePubMedGoogle Scholar
- Lu L, Zhang Q, Wu K, Chen X, Zheng Y, Zhu C, Wu J. Hepatitis C virus NS3 protein enhances cancer cell invasion by activating matrix metalloproteinase-9 and cyclooxygenase-2 through ERK/p38/NF-kappaB signal cascade. Cancer Lett. 2015;356(2 Pt B):470–8.View ArticlePubMedGoogle Scholar
- Liu Y, Xu Y, Ma H, Wang B, Xu L, Zhang H, Song X, Gao L, Liang X, Ma C. Hepatitis B virus X protein amplifies TGF-beta promotion on HCC motility through down-regulating PPM1a. Oncotarget. 2016;7(22):33125–35.